Skip to search boxSkip to navigationSkip to main content

MYC protein expression is an important prognostic factor in acute myeloid leukemia

  • Maro Ohanian(corresponding author)
    ,
  • Uri Rozovski
    ,
  • Rashmi Kanagal-Shamanna
    ,
  • Lynne V. Abruzzo
    ,
  • Sanam Loghavi
    ,
  • Tapan Kadia
*Corresponding author for this work
  • University of Texas Health Science Center at Houston
    ,
  • Tel Aviv University
    ,
  • Ohio State University
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

As new drugs targeting MYC show clinical activity in acute myeloid leukemia (AML), understanding MYC expression in AML is of critical importance. We assessed MYC protein expression by immunohistochemistry in bone marrow of patients with untreated AML (n = 265). Overall, 90% of patients demonstrated MYC overexpression and MYC immunopositivity ≤6% was associated with superior complete remission (CR) duration of 23 months versus 12 months for MYC immunopositivity >6% (p =.028). Among 241 patients at higher risk for relapse, including those ≥55 years of age and patients with intermediate- and high-risk AML, MYC immunopositivity ≤6% conferred significantly superior median overall survival (OS) (24 versus 13 months; p =.042), event-free survival (EFS) (14 versus 6 months; p =.048), and relapse-free survival (RFS) (25 versus 12 months; p =.024). The prognostic impact of MYC-immunopositivity was retained on multivariate analysis of OS, EFS, and RFS. We conclude that MYC immunopositivity is an important prognostic factor in patients with untreated AML, particularly those at higher risk for relapse.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 37-48 (12 pages)

Journal (Volume, Issue Number)

Leukemia and Lymphoma (Volume 60, Issue 1)

Publication milestones

  • Published - 01/02/2019

Publication status

Published - 01/02/2019

ISSN

1042-8194

Publication IDs

  • Scopus: 85046688405
  • PubMed: 29741984
  • ORCID: /0000-0002-8636-1071/work/68887836

Publication metrics

Metrics

Fractional count
1
Fractional count
0.03
Fractional count
29
Fractional count
0.97
Fractional count
1
Fractional count
1
SciVal
citations
22
SciVal
FWCI
2.95
SciVal
Author count
30
SciVal
Paper percentile
96
SciVal
Top percentile
5
Scopus
citations

PlumX, opens in new tab

Citation count
75
Captures
72
Mentions
7

Funding Details

This work was supported in part by Leukemia SPORE Grant P50CA100632 from the National Institutes of Health. SMP was supported by a National Cancer Institute/National Institutes of Health Award (R01CA207204).
FundersFunding numbers
National Institutes of Health, National Cancer Institute
R01CA207204
NIH
-
NCATS
TL1TR000369